Taiwanese diagnostics developer Advanced Biomed slashes deal size by 92% ahead of $9 million US IPO
Advanced Biomed, a Taiwanese developer of microfluidic testing equipment for early cancer screening, lowered the proposed deal size for its upcoming IPO on Monday. In its latest filing, the company also replaced sole bookrunner Univest Securities with Craft...read more